Navigation Links
Study finds hormones can change the breast's genetic material
Date:1/31/2013

Melbourne scientists have discovered how female steroid hormones can make dramatic changes to the genetic material in breast cells, changes that could potentially lead to breast cancer.

Researchers from the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, have identified how pregnancy hormones send signals to critical molecules on the DNA to make changes in the epigenome. The epigenome is a series of chemical tags that modify DNA, controlling which genes are switched on and off.

Professor Jane Visvader, Dr Bhupinder Pal, Professor Geoff Lindeman and colleagues from the institute's breast cancer laboratory led the study, which was published today in Cell Reports.

Professor Visvader said the researchers had created a roadmap of the epigenomes of different breast cell types. In collaboration with Professor Gordon Smyth and colleagues from the institute's Bioinformatics division they determined how the epigenomes changed in response to ovarian hormones such as progesterone.

"We found the epigenome was very sensitive to hormonal regulation," Professor Visvader said. "This reveals another way in which female hormones can influence breast cancer risk - by altering the epigenome through modifications in DNA tags."

The epigenome is where the DNA and the environment intersect, communicating signals from the outside world to the DNA. The epigenome doesn't alter the genetic code, but is a layer of proteins that sits 'on top' of the DNA and provides instructions on whether DNA should be read and 'switched on' to produce proteins.

The research team found that pregnancy hormones activate a molecule called EZH2, which is an important modifier of the epigenome. "We found that hormones including progesterone activate EZH2 to modify the epigenome, leading to global changes in the expression of a huge number of genes," Professor Visvader said.

"In normal tissue, EZH2 is essential for the development of breast tissue including ducts and milk-producing cells, and for maintaining the activity of breast stem cells and their daughter progenitor cells. However, life-long exposure to hormones could lead to breast tumour initiation through increased levels of EZH2 and the changes that it orchestrates in the epigenome."

Breast cancer is the most common cause of cancer in women, accounting for almost 30 per cent of all cancers affecting women. One in nine women in Australia will develop breast cancer by the age of 85.

High levels of EZH2 are a marker of poor prognosis in breast cancer and have been frequently observed in basal-like breast cancers, the most aggressive types of breast cancer. "The link between progesterone, EZH2 and the epigenome, could be crucially important in the very early stages of breast cancer development," Professor Visvader said.

Professor Lindeman said there were decades of evidence linking hormone exposure with breast cancer, but the hormones' influence on the epigenome was not known. "Our discovery points to a role for hormone-induced changes in the epigenome in the early stages of breast cancer initiation, and could lead to new therapeutics for treating breast cancer," Professor Lindeman said. "Inhibitors against EZH2 are being developed by others, but it will be several years before we know the outcome of these on cancer."


'/>"/>
Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: